Valsartan

Valsartan
Product Description

Dr. Reddy’s has the capabilities and capacities to manufacture and deliver sartan APIs in accordance with global regulations. Our team of experts developed processes and the analytical methods to avoid the presence of nitrosamine impurities, which are already suitable to confirm future requirements of the EMA (NDEA or NDMA limits of <0.03 ppm). 

Dr. Reddy's Laboratories SA

  • Country/Region:
    Switzerland
  • On CPHI since:
    2015
  • Certificates:
    3
  • Employees:
    5000+
Company types
Generics/Biosimilars Manufacturer
Primary activities
API Producer
Chemical Development
Generic APIs producer
Pharmaceutical Company (generic finished products)
Specifications
  • CAS Registry Number
    137862-53-4
  • Supplied from
    India

Dr. Reddy's Laboratories SA

  • Country/Region:
    Switzerland
  • On CPHI since:
    2015
  • Certificates:
    3
  • Employees:
    5000+
Company types
Generics/Biosimilars Manufacturer
Primary activities
API Producer
Chemical Development
Generic APIs producer
Pharmaceutical Company (generic finished products)

More Products from Dr. Reddy's Laboratories SA (2)

  • Peptides

    Product Peptides

    We help to accelerate the time-to-market of your peptide APIs and formulations Dr. Reddy's peptide unit has decades of experience in process development and production of peptide APIs and formulations. This experience is brought to bear on a comprehensive offering that integrates a continuum of services ...
  • Losartan Potassium

    Product Losartan Potassium

    Dr. Reddy’s has the capabilities and capacities to manufacture and deliver sartan APIs in accordance with global regulations. Our team of experts developed processes and the analytical methods to avoid the presence of nitrosamine impurities, which are already suitable to confirm future requirements of ...

Dr. Reddy's Laboratories SA resources (1)

  • Brochure Sugammadex Sodium API article

    Sugammadex sodium is one of the key molecules in Dr. Reddy’s API portfolio and an ideal use case on how a thorough understanding of the interaction between API and formulation can significantly improve the robustness of the formulation process considering the drug substance’s proneness to degradation in the formulation process, specifically during the terminal sterilization (TS) process for intravenous injection.